Overview

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

Status:
Completed
Trial end date:
2018-09-12
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.